Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Immunitybio Inc IBRX

Healthcare Biotechnology
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as... see more

Recent & Breaking News (NDAQ:IBRX)

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 22, 2023

ImmunityBio to Participate in the Jefferies Global Healthcare Conference

Business Wire May 22, 2023

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 21, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 20, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

PR Newswire May 19, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 17, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire May 15, 2023

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages ImmunityBio (IBRX) Investors with Substantial Losses to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations Regarding FDA Complete Response Letter

Newsfile May 15, 2023

INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 15, 2023

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire May 12, 2023

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire May 12, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm

Business Wire May 11, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ImmunityBio Inc. (IBRX) Investigation

Business Wire May 11, 2023

National Multicenter Trial Opens to Study ImmunityBio's Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome

Business Wire April 25, 2023

ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University

Business Wire April 24, 2023

ImmunityBio to Present 'Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG' at ASCO GU

Business Wire February 16, 2023

ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors

Business Wire February 15, 2023

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

Business Wire January 19, 2023

ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor

Business Wire December 12, 2022

ImmunityBio to Participate in 34th Annual Piper Sandler Healthcare Conference

Business Wire November 17, 2022